Approval · Notice of Compliance 28538 · 2022
ENTYVIO: Notice of Compliance 28538
Issued July 6, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28538
- Date
- July 6, 2022
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENTYVIO | Not yet assigned | — |
Medicinal ingredients
- VEDOLIZUMAB 300 MG per VIAL
- VEDOLIZUMAB 108 MG per PEN